COMMUNIQUÉS West-GlobeNewswire

Orvida Pharma Announces FDA Acceptance of KM-023 (ontivatrep) into Rare Disease Evidence Principles Process for Olmsted Syndrome
14/10/2026
FDA’s Rare Disease Evidence Principles ( RDEP) process aims to provide greater speed and predictability in the review of therapies for rare diseases with significant unmet medical need Acceptance enables engagement with [...]
Matchpoint Therapeutics Expands Leadership Team with Appointment of John O’Malley, M.D., Ph.D., as Chief Medical Officer
14/10/2026
Dr. O’Malley brings deep immunology clinical development expertise, with previous leadership roles at CRISPR Therapeutics and Sanofi Appointment follows Matchpoint’s recent $150M Series B financing to advance pipeline [...]
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
14/10/2026
-- Company to receive ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 -- -- ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027 -- BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- [...]
Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome
14/10/2026
FLINTLOCK Phase 2 clinical trial will evaluate the safety, tolerability, pharmacokinetics, and clinical efficacy of high-dose monoclonal antibody VYD2311 in adults aged 18-65 years with Long COVID or Post-Vaccination [...]
Purespring Therapeutics to present new data on pipeline progress in Alport Syndrome at the American Society of Nephrology (ASN) Kidney Week 2026
14/10/2026
New preclinical data demonstrates PS-003 restores the key collagen protein missing in X-linked Alport Syndrome (XLAS) and is presented alongside findings from one of the largest genetic studies of Alport Syndrome to [...]
Glass House Brands Receives Good Agricultural and Collection Practice (GACP) Certifications
14/10/2026
GACP Certification from Perry Johnson Supports Pathway to International Markets This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated June 10, 2026, to [...]
TULSA Abstracts at the 15th Interventional MRI Symposium Strengthen Real-World Evidence, Clinical Differentiation, and Platform Expansion Opportunity
14/10/2026
TORONTO, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) today announced that five abstracts presented at the 15th Interventional MRI (“iMRI”) Symposium in [...]
Rhea’s Factory Partners with Niagara Bottling on Industrial Validation of Enzymatic PET Recycling Through U.S. Department of Energy Program
14/10/2026
One of the first industrial deployments of enzymatic PET recycling in the world will validate Rhea’s Factory’s AI-designed enzymes and end-to-end process as a complement to Niagara Bottling’s mechanical recycling [...]
CAMP4 to Participate in Chardan’s 10th Annual Healthcare Conference
14/10/2026
WATERTOWN, Mass., Oct. 14, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics [...]
Tvardi Therapeutics to Participate in Chardan’s 10th Annual Healthcare Conference
14/10/2026
HOUSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule [...]
Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026
14/10/2026
First clinical data for leniolisib in a larger group of PID participants beyond APDS, supporting the potential of targeted PI3Kδ inhibition to address immune dysregulation Leniolisib was well-tolerated, with benefits [...]
Orion publishes Interim Report for January–September 2026 and holds a webcast on 28 October 2026
14/10/2026
ORION CORPORATION PRESS RELEASE 14 OCTOBER 2026 at 9.00 EEST Orion publishes Interim Report for January–September 2026 and holds a webcast on 28 October 2026 Orion will publish Interim Report for January–September 2026 [...]
Sapreme Therapeutics announces oral presentation of new preclinical data on lead Duchenne muscular dystrophy candidate SPM-2551 at OTS 2026
14/10/2026
SPM-2551 demonstrated robust and durable pharmacological activity following a single low-dose administration in preclinical Duchenne muscular dystrophy (DMD) models Data support Sapreme's proprietary SPT platform, [...]
Nxera Pharma Enters into Exclusive License, Supply and Commercialization Agreement with Synmosa for QUVIVIQ® (daridorexant) Across Eight Asia-Pacific Markets
14/10/2026
Synmosa to lead regulatory approvals, market access, distribution and sales in Singapore, Thailand, Indonesia, Malaysia, the Philippines, Vietnam, Australia and New Zealand. Nxera to supply drug product and receive an [...]
Engitix appoints Ryan Richardson to Board of Directors as company advances towards clinical development
14/10/2026
LONDON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Engitix Ltd., a biotechnology company pioneering extracellular matrix (ECM)-based drug discovery and development in oncology, fibrosis and fibro-inflammatory diseases, today [...]
seragy Launches with €12 Million Financing to Advance Quantitative Biomarkers for Neurodegenerative Diseases
14/10/2026
Development of quantitative biomarker strategies for proteopathies through seragy’s proprietary Se RAS ® technology Expansion of the company’s laboratory and analytical capabilities with funding from Commerzbank, the [...]
Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg
14/10/2026
AVT29 submitted to the European Medicines Agency as a line extension to the existing marketing authorization for Mynzepli ® (aflibercept 2 mg) High-dose aflibercept offers the potential to reduce treatment frequency for [...]
Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg
14/10/2026
AVT29 submitted to the European Medicines Agency as a line extension to the existing marketing authorization for Mynzepli® (aflibercept 2 mg) High-dose aflibercept offers the potential to reduce treatment frequency for [...]
Phonak launches Roger On Sphere™: the first AI-powered remote microphone to separate speech from noise in real time
14/10/2026
STÄFA, Switzerland, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Phonak today announced Roger On Sphere™, the world's first remote microphone powered by a deep neural network (DNN) that separates speech from background noise in [...]

Pages